JIC
ACOR

Joel Isaacson & Co’s Acorda Therapeutics ACOR Stock Holding History

Joel Isaacson & Co’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-4
Closed -$12K – 779
2016
Q1 		$12K Hold
4
– – ﹤0.01% 553
2015
Q4 		$20K Hold
4
– – ﹤0.01% 466
2015
Q3 		$12K Hold
4
– – ﹤0.01% 555
2015
Q2 		$15K Hold
4
– – ﹤0.01% 544
2015
Q1 		$15K Hold
4
– – ﹤0.01% 533
2014
Q4 		$19K Buy
+4
New +$17.2K 0.01% 444

Other funds holding ACOR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Joel Isaacson & Co's ACOR Position: Q2 2016 in Review

Joel Isaacson & Co sold out of Acorda Therapeutics (ACOR) in Q2 2016, closing a stake of 4 shares — an estimated $12K sold.

Joel Isaacson & Co first reported a position in ACOR in Q4 2014 and held it in 6 quarters. The position peaked at $20K in Q4 2015. 175 funds tracked by Wall St. Rank hold ACOR as of Q2 2016.

  • Joel Isaacson & Co reported no remaining Acorda Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Joel Isaacson & Co sold 4 Acorda Therapeutics shares in Q2 2016, an estimated $12K.
  • Joel Isaacson & Co first reported a position in Acorda Therapeutics in Q4 2014 and held it in 6 quarters.
  • Joel Isaacson & Co's Acorda Therapeutics position peaked at $20K in Q4 2015.
  • 175 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q2 2016.

Based on Joel Isaacson & Co's 13F filing for Q2 2016, filed 22 Jul 2016.